<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099577</url>
  </required_header>
  <id_info>
    <org_study_id>SGH201708</org_study_id>
    <nct_id>NCT03099577</nct_id>
  </id_info>
  <brief_title>PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of PET/CT-directed Hyperfractionated Radiation Dose Escalation With Concurrent Weekly Carboplatin and Paclitaxel in Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find the maximum tolerable dose of radiation that can be
      delivered combined with chemotherapy (carboplatin &amp; paclitaxel) in patients with stage III
      non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiotherapy is the standard of care for unresectable stage III NSCLC based
      on the results of phase III randomised trials. The current standard radiation therapy dose
      has remained 60- Gy at -2 Gy/fraction for nearly four decades (60Gy), with local disease
      control rates of approximately 50% and a median overall survival of only 18 months.These
      results are suboptimal and more effective treatment regimens are needed.

      We hypothesize that hyperfractionated radiation dose escalation to residual tumor volumes
      after standard chemoradiotherapy as defined by positron emission tomography (PET) /computed
      tomography (CT) would improve local control and overall survival while reducing the acute and
      late normal tissue toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2017</start_date>
  <completion_date type="Anticipated">June 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>1 year</time_frame>
    <description>Maximum Tolerated Dose is defined as CTCAE 4 grade 3 acute radiation-related toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Local Failure</measure>
    <time_frame>2 years</time_frame>
    <description>Local control will be assessed radiographically using endoscopy with biopsy and a positron emission computed tomography-CT scan</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 64.8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 69.6 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 74.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 79.2 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 84 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 88.8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 93.6 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 1</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 2</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 3</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 4</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 5</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 6</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 7</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 7</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen 7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have FDG-avid and histologically or cytologically proven non-small cell
             lung cancer.

          2. Age 1 8-75.

          3. Zubrod performance status 0-2.

          4. Stage III ( American Joint Committee on Cancer AJCC, 7th ed.).

          5. No prior radiation to the thorax that would overlap with the current treatment field.

          6. Adequate bone marrow, renal and hepatic functions as assessed by the following:
             Hemoglobin &gt;/= 10.0 g/dl, Platelet count &gt;/= 1 00,000/mm^3,absolute granulocyte count
             (AGC) ≥2 × 10^9 cells/L,bilirubin and Aspartate transaminase ≤1.5 ×upper limit of
             normal (ULN), Creatinine &lt;/=1 .5 times ULN.

          7. A signed informed consent must be obtained prior to therapy.

          8. Induction chemotherapy is allowed.

          9. Life expectancy more than 3 months.

        Exclusion Criteria:

          1. Patients with any component of small cell lung carcinoma are excluded from this study.

          2. Patients with evidence of a malignant pleural or pericardial effusion are excluded.

          3. Prior radiotherapy that would overlap the radiation fields.

          4. Uncontrolled concurrent illness including, but not limited to: Chronic Obstructive
             Pulmonary Disease(COPD) exacerbation or other respiratory illness, serious
             uncontrolled infection, symptomatic congestive heart failure (CHF),unstable angina
             pectoris, uncontrolled hypertension,or psychiatric illness/social situations that
             would limit compliance with the study requirements.

          5. Known hypersensitivity to paclitaxel.

          6. Any other condition or circumstance that would, in the opinion of the Investigator,
             make the patient unsuitable for participation in the study.

          7. Acquired Immune Deficiency Syndrome.

          8. Conditions precluding medical follow-up and protocol compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingfeng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the ethic committee of shanghai genernal hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ningning Cheng, MD</last_name>
    <phone>37798364</phone>
    <phone_ext>8119</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Liu, MD</last_name>
    <phone>37798364</phone>
    <phone_ext>8119</phone_ext>
    <email>drliuyrt@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the Ethic Committee of Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhixiao Chen, MD</last_name>
      <phone>021-63240090</phone>
      <phone_ext>6218</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chen tingfeng</investigator_full_name>
    <investigator_title>director,department of radioation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

